Clinical Research, Pharma & Healthcare FinancingPepGen Shifts Focus to DM1 Program After PGN-EDO51 UpdateBusiness WireMay 29, 2025June 2, 2025 by Business WireMay 29, 2025June 2, 2025091 – PGN-EDO51 did not achieve target dystrophin levels in CONNECT1-EDO51 trial; Company to discontinue development of DMD programs – – PGN-EDO51 at 10 mg/kg was...